[go: up one dir, main page]

SI1896590T1 - Stabilna transfekcija brez seruma in proizvajanje rekombinantnih humanih proteinov v humanih celičnih linijah - Google Patents

Stabilna transfekcija brez seruma in proizvajanje rekombinantnih humanih proteinov v humanih celičnih linijah

Info

Publication number
SI1896590T1
SI1896590T1 SI200632064A SI200632064A SI1896590T1 SI 1896590 T1 SI1896590 T1 SI 1896590T1 SI 200632064 A SI200632064 A SI 200632064A SI 200632064 A SI200632064 A SI 200632064A SI 1896590 T1 SI1896590 T1 SI 1896590T1
Authority
SI
Slovenia
Prior art keywords
serum
production
cell lines
stable transfection
free stable
Prior art date
Application number
SI200632064A
Other languages
English (en)
Inventor
Haiyan Ding
Cathleen Wegmann
Carola JUSTEL
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35427852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1896590(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of SI1896590T1 publication Critical patent/SI1896590T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21001—Chymotrypsin (3.4.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/007—Vectors comprising a special origin of replication system tissue or cell-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SI200632064A 2005-06-30 2006-06-29 Stabilna transfekcija brez seruma in proizvajanje rekombinantnih humanih proteinov v humanih celičnih linijah SI1896590T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05105965A EP1739179A1 (en) 2005-06-30 2005-06-30 Serum-free stable transfection and production of recombinant human proteins in human cell lines
EP06777525.4A EP1896590B1 (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines
PCT/EP2006/063705 WO2007003582A2 (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines

Publications (1)

Publication Number Publication Date
SI1896590T1 true SI1896590T1 (sl) 2016-07-29

Family

ID=35427852

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200632064A SI1896590T1 (sl) 2005-06-30 2006-06-29 Stabilna transfekcija brez seruma in proizvajanje rekombinantnih humanih proteinov v humanih celičnih linijah

Country Status (20)

Country Link
US (4) US8871439B2 (sl)
EP (2) EP1739179A1 (sl)
JP (3) JP5925407B2 (sl)
KR (1) KR101320489B1 (sl)
CN (2) CN105755041A (sl)
AU (1) AU2006265173B2 (sl)
BR (1) BRPI0613721B1 (sl)
CA (1) CA2611708C (sl)
DK (1) DK1896590T3 (sl)
ES (1) ES2574584T3 (sl)
HU (1) HUE028028T2 (sl)
IL (3) IL266122B2 (sl)
MX (1) MX2007015370A (sl)
NO (1) NO343221B1 (sl)
PL (1) PL1896590T3 (sl)
RU (1) RU2453597C2 (sl)
SI (1) SI1896590T1 (sl)
UA (1) UA99700C2 (sl)
WO (1) WO2007003582A2 (sl)
ZA (1) ZA200711013B (sl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101190605B1 (ko) * 2007-06-15 2012-10-15 재단법인 목암생명공학연구소 활성형 재조합 혈액응고 9인자의 대량생산 방법
AU2009264282B2 (en) 2008-06-24 2013-04-18 Octapharma Ag A process of purifying coagulation factor VIII
EP2331569A1 (en) * 2008-08-21 2011-06-15 Octapharma AG Recombinantly produced human factor viii and ix
JP5592080B2 (ja) * 2009-05-08 2014-09-17 株式会社日立製作所 細胞培養方法、細胞培養システム
CN101906438B (zh) * 2009-06-05 2013-04-24 苏州泽璟生物制药有限公司 一种重组人凝血因子ⅶ在动物细胞内的表达和生产方法
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
JP5876868B2 (ja) 2010-03-30 2016-03-02 オクタファルマ・アーゲー 第ｉｘ凝固因子などのビタミンｋ依存性タンパク質の精製方法
CA2793143C (en) 2010-03-30 2020-04-28 Gustav Gilljam Process for the purification of a growth factor protein
BR112012027055B1 (pt) 2010-04-20 2019-09-17 Octapharma Ag Método para estabilizar uma proteína do plasma de sangue humano, composição, e uso da melezitose
EP2707387B1 (en) * 2011-05-13 2019-12-25 Octapharma AG A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
CN103031277B (zh) * 2011-09-29 2015-07-15 重庆大学 力生长因子在制备无血清培养耐受型哺乳动物工程细胞中的应用
CN103305540B (zh) * 2012-03-14 2015-03-25 齐鲁制药有限公司 一种用于生物学活性测定的质粒及其制备方法
US10066000B2 (en) 2012-05-02 2018-09-04 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
SG11201508447TA (en) * 2013-05-03 2015-11-27 Fujifilm Diosynth Biotechnologies Uk Ltd Expression process
AU2014318890B2 (en) 2013-09-12 2019-03-07 Biomarin Pharmaceutical Inc. Adeno-associated virus Factor VIII vectors
US10822393B2 (en) 2014-01-20 2020-11-03 Octapharma Ag Process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII/AG
EP3212793B1 (en) 2014-11-02 2020-01-08 Arcturus Therapeutics, Inc. Messenger una molecules and uses thereof
EP3625329A1 (en) 2017-05-17 2020-03-25 Octapharma AG Method for the production of a recombinant target protein
CN112154344B (zh) 2018-05-04 2024-07-19 弗劳恩霍夫应用研究促进协会 利用磁化的反转状态的评估的动脉自旋标记
CN113164947B (zh) * 2018-12-06 2023-12-01 巴斯夫欧洲公司 包含沸石材料和锆螯合配合物的水性悬浮液
CN110438066B (zh) * 2019-08-19 2021-01-12 杭州百凌生物科技有限公司 一种可稳定传代的可悬浮培养的哺乳动物细胞系293 c18p及其制备方法和应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
ATE78871T1 (de) 1984-01-12 1992-08-15 Chiron Corp Proteinzusammensetzung mit koagulations-wirkung und verfahren zu ihrer herstellung.
FI86885C (fi) 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
JPS6171774A (ja) 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
DE3683980D1 (de) 1985-04-12 1992-04-02 Genetics Inst Neue prokoagulierungsproteine.
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
FI98829C (fi) 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
EP0251843A1 (fr) 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
DK155388C (da) 1986-07-08 1989-10-23 Palle Pedersen Laas
EP0254076B1 (en) 1986-07-11 1991-05-08 Miles Inc. Improved recombinant protein production
IL83192A (en) 1986-07-18 1992-11-15 Gist Brocades Nv Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
IL84168A0 (en) 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
EP0294910B1 (en) 1987-06-12 1996-09-11 Immuno Ag Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
JPH084495B2 (ja) * 1988-08-19 1996-01-24 帝人株式会社 接着性動物細胞の培養方法
KR927003812A (ko) 1989-11-17 1992-12-18 노보 노르디스크 아크티에 셀스카브 인자 viii:c 활성을 갖는 단백질 복합체 및 그의 제조
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4204694C3 (de) 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
JPH08506498A (ja) 1993-02-09 1996-07-16 オクタファルマ・アクチエンゲセルシャフト 非脂質被覆ウイルスの失活方法
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
DK128093D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
US6136865A (en) 1995-05-20 2000-10-24 Octapharma Ag Method for reduction of the infectiousness of potentially infectious material
AU735763B2 (en) * 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
PT1071747E (pt) * 1998-04-17 2004-12-31 Nestle Sa Linhas celulares imortalizadas derivadas de tecidos cutaneos humanos normais
US6210924B1 (en) * 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
CA2252972C (en) * 1998-11-26 2012-09-18 National Research Council Of Canada Serum-free production of recombinant proteins and adenoviral vectors
EP1010762A1 (en) * 1998-12-02 2000-06-21 Aventis Behring Gesellschaft mit beschränkter Haftung DNA constructs of blood clotting factors and P-Selectin
CA2370477C (en) * 1999-04-15 2010-06-29 Crucell Holland B.V. Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
AU4286100A (en) * 1999-04-29 2000-11-17 Leukotech A/S Expression of heparin-binding protein in recombinant mammalian cells
IL148060A0 (en) * 1999-08-25 2002-09-12 Immunex Corp Compositions and methods for improved cell culture
DE60115613T2 (de) 2000-03-22 2006-08-24 Octagene Gmbh Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
KR20030024799A (ko) * 2000-07-20 2003-03-26 뉴로젠 코포레이션 캡사이신 수용체 리간드
WO2002099089A1 (en) * 2001-06-04 2002-12-12 Corixa Corporation Compositions and methods for high-level, large-scale production of recombinant proteins
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
DK1567652T3 (da) 2002-11-29 2007-11-26 Boehringer Ingelheim Pharma Nye neomycin-phosphotransferasegener og fremgangsmåde til selektion af höjtproducerende rekombinante celler
US7217566B2 (en) * 2003-03-24 2007-05-15 Invitrogen Corporation Attached cell lines
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
EP3037105B1 (en) * 2003-06-27 2021-03-17 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
JP2005073509A (ja) * 2003-08-28 2005-03-24 Nihon Pharmaceutical Co Ltd ヒトアンチトロンビンの生産方法
JP4684108B2 (ja) * 2003-10-03 2011-05-18 恵一 福田 幹細胞から心筋細胞を分化誘導する方法
CN1875100A (zh) * 2003-11-06 2006-12-06 埃克森希特医疗股份有限公司 BACE455,人β－分泌酶的可变剪接变体
JP4705473B2 (ja) * 2003-11-06 2011-06-22 株式会社リプロセル 幹細胞の凍結保存法およびシステム
WO2009101560A2 (en) 2008-02-15 2009-08-20 Koninklijke Philips Electronics N.V. Apparatus for segmenting an object comprising sub-objects

Also Published As

Publication number Publication date
JP6754414B2 (ja) 2020-09-09
IL266122A (en) 2019-06-30
US20100184141A1 (en) 2010-07-22
KR20080028891A (ko) 2008-04-02
BRPI0613721B1 (pt) 2022-05-24
WO2007003582A2 (en) 2007-01-11
CN105755041A (zh) 2016-07-13
IL250575A0 (en) 2017-03-30
US20160177362A1 (en) 2016-06-23
IL187676A0 (en) 2008-08-07
HUE028028T2 (en) 2016-11-28
JP5925407B2 (ja) 2016-05-25
MX2007015370A (es) 2008-02-11
IL266122B2 (en) 2025-07-01
AU2006265173A1 (en) 2007-01-11
ES2574584T3 (es) 2016-06-20
UA99700C2 (ru) 2012-09-25
US9273325B2 (en) 2016-03-01
US8871439B2 (en) 2014-10-28
CA2611708A1 (en) 2007-01-11
EP1896590B1 (en) 2016-03-23
JP2016154537A (ja) 2016-09-01
WO2007003582A3 (en) 2007-05-18
RU2008103319A (ru) 2009-08-10
US20170152523A1 (en) 2017-06-01
DK1896590T3 (da) 2016-06-13
EP1896590A2 (en) 2008-03-12
AU2006265173B2 (en) 2011-07-28
US20150044720A1 (en) 2015-02-12
RU2453597C2 (ru) 2012-06-20
US9796986B2 (en) 2017-10-24
BRPI0613721A2 (pt) 2011-02-08
JP2019058173A (ja) 2019-04-18
CA2611708C (en) 2019-11-12
PL1896590T3 (pl) 2016-10-31
IL187676A (en) 2017-02-28
IL266122B1 (en) 2025-03-01
EP1739179A1 (en) 2007-01-03
NO343221B1 (no) 2018-12-10
KR101320489B1 (ko) 2013-10-30
ZA200711013B (en) 2008-10-29
NO20076087L (no) 2008-01-28
CN101233238A (zh) 2008-07-30
US9512457B2 (en) 2016-12-06
JP2008544750A (ja) 2008-12-11

Similar Documents

Publication Publication Date Title
IL250575A0 (en) Stable serum-free cell-to-cell gene transfer and production of recombinant human proteins in human cell lines
HUE038039T2 (hu) mRNS bejuttatása fehérjék és enzimek kiegészítésére humán genetikai betegségekben
IL262205A (en) Protein formulations and methods for their preparation
EP2102355A4 (en) PROTEINS AND PEPTIDES WITH EXTENDED ACTION AND METHODS OF PRODUCTION AND USE THEREOF
IL200622A0 (en) Use of copper and glutamate in cell culture for production of polypeptides
ZA200805920B (en) Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
EP2102237A4 (en) RECOMBINANT HUMAN FACTOR IX AND USE THEREOF
IL197917A0 (en) Genetic incorporation of unnatural amino acids into proteins in mammalian cells
EP1758617A4 (en) STABLE LIQUID AND LYOPHILIZED PROTEIN FORMULATIONS
EP2234636A4 (en) FORMULATIONS OF STABILIZED PEPTIDES AND PROTEINS
PL1863905T3 (pl) Sposób aktywacji naturalnych komórek zabójców preparatami komórek guza in vitro
EP2297331A4 (en) METHOD AND COMPOSITIONS FOR PRODUCING A RECOMBINANT PROTEIN IN MAMMALIAN CELLS WITH HBX EXPRESSION
IL207174A (en) An isolated peptide capable of stimulating the production of one or more extracellular matrix proteins in fibroblast cells, its pharmacological composition and its use
GB2442271B (en) An in vitro human skin assay protocol which directly uses the natural cellular interactions between un-manipulated autologous human epidermal and dermal cells
IL188824A (en) Plant cells expressing recombinant human glucosrybridosidase and their use as a drug
AU2004906554A0 (en) Derivation and culture of human embryo-derived cells
HK1120523A (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
GB0423516D0 (en) Improvements in and relating to polypeptide molecules and libraries of polypeptide molecules
AU2006901819A0 (en) In VIVO stimulation of cellular material
AU2005904150A0 (en) Delivery of proteins and peptides
IL192438A0 (en) Stable enzymatic preparations and methods of use thereof